Liu Zhixian, Sun Qingrong, Wang Xiaosheng
Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
School of Science, China Pharmaceutical University, Nanjing 211198, China.
Transl Oncol. 2017 Feb;10(1):22-32. doi: 10.1016/j.tranon.2016.10.003. Epub 2016 Nov 24.
Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive its progression. PLK1 overexpression has been found in a variety of human cancers and was associated with poor prognoses in cancers. Many studies have showed that inhibition of PLK1 could lead to death of cancer cells by interfering with multiple stages of mitosis. Thus, PLK1 is expected to be a potential target for cancer therapy. In this article, we examined PLK1's structural characteristics, its regulatory roles in cell mitosis, PLK1 expression, and its association with survival prognoses of cancer patients in a wide variety of cancer types, PLK1 interaction networks, and PLK1 inhibitors under investigation. Finally, we discussed the key issues in the development of PLK1-targeted cancer therapy.
Polo样激酶1（PLK1）在有丝分裂的起始、维持和完成过程中发挥着重要作用。PLK1功能失调可能促进癌细胞转化并推动其进展。在多种人类癌症中都发现了PLK1的过表达，并且与癌症的不良预后相关。许多研究表明，抑制PLK1可通过干扰有丝分裂的多个阶段导致癌细胞死亡。因此，PLK1有望成为癌症治疗的潜在靶点。在本文中，我们研究了PLK1的结构特征、其在细胞有丝分裂中的调控作用、PLK1的表达及其与多种癌症类型中癌症患者生存预后的关系、PLK1相互作用网络以及正在研究的PLK1抑制剂。最后，我们讨论了PLK1靶向癌症治疗开发中的关键问题。
Zotero 插件
